medigraphic.com

2019, Number 2

<< Back Next >>

Enf Infec Microbiol 2019; 39 (2)

Antimicrobial resistance in bacteria isolated from infections associated with health care in a second level hospital

Galván MMF, Flores SN, Morales CME, Álvarez MSL

Language: Spanish
References: 25
Page: 49-55
PDF size: 383.72 Kb.


ABSTRACT

Background. Antimicrobial resistance origin is multicausal; currently contributes with more than 700 thousand deaths in the world, and it is expected that by the year 2050 it will cause about 10 million deaths per year with a cost around 100 000 million dollars. Impact is more severe in emerging countries such as Mexico.
Material and Method. Descriptive, observational and retrospective study. There were reviewed 348 files from January 2017 to September 2018; 273 cases of bacterial infections were included. Cultures and antimicrobial susceptibility were processed using the VITEK-2 Compact® equipment from bioMerieux®. The information was captured in Excel® and analyzed in SPSS® v 22.
Results. Staphylococcus spp. (27.4%), E. coli (25.6%) and Pseudomonas spp. (18.7%) were the most prevalent bacteria. 44.7% of the 273 cases presented some marker of resistance. There was no antimicrobial resistance to ertapenem and linezolid; amikacin, tigecycline and meropenem presented 17.1, 23.9 and 30%, respectively. The antibiotics of greater cost to the institution were ertapenem, tigeciclina and meropenem (› 200 Mexican pesos); in contrast, gentamicin, ciprofloxacin and amikacin had the lowest cost (‹5 Mexican pesos).
Conclusions. There was high resistance to tigecycline and meropenem. There are less expensive antibiotics with equal or greater effectiveness than drugs with a high economic impact.


REFERENCES

  1. Eiamphungporn, W., Schaduanfrat, N., Malik, A.A. y Nantasenamat, Ch., “Tackling the antibiotics resistance caused by clase a β-lactamases through the use of β-lactamase inhibitory protein”, Int J Mol Sci, 2018, 19: 2222.

  2. O’Neill, J., “Tackling drug-resistant infections globally: final report and recommendations”, Rev Antimicrob Res, 2015.

  3. Blair, J.M., Webber, M.A., Baylay, A.J., Oqbolu, D.O. y Piddock, L.J., “Molecular mechanisms of antibiotics resistance”, Nat Rev Microbiol, 2015, 13 (1): 42-51.

  4. Petchiappan, A. y Chatterji, D., “Antibiotic resistance: current perspectives”, acs Omega, 2017, 2: 7400-7409.

  5. The Review of Antimicrobial Resistance, “Tacking drug resistant globally, marzo de 2016, disponible en: http:// amr-review.org/sites/default/files/Tackling%20.

  6. Zaman, S.B., Hussain, M.A., Nye, R., Mehta, V., Mamun, K.T. y Hossain, N., “A review on antibiotic resistance: alarm bells are ringing”, Cureus, 2017, 9 (6): e1403.

  7. Lee Ventola, C., “The antibiotic resistance crisis”, pt, 2015, 40 (4): 277-283.

  8. Centers for Disease Control and Prevention, Office of Infectious Disease Antibiotic resistance threats in the United States, 2013, abril de 2013, disponible en: http:// www.cdc.gov/drugresistance/threat-report-2013.

  9. Hollis, A. y Ahmed, Z., “Preserving antibiotic, rationally”, N Engl J Med, 2013, 369 (26): 2472-2474.

  10. Cuong, N.V., Padungtod, P., Thwaites, G. y Carrique-Mas, J., “Antimicrobial usage in animal production: a review of the literature with a focus on low-and middle-income countries”, Antibiotics, 2018, 7 (75).

  11. Van Boeckel, T.P., Browe, C., Gilbert, M., Grenfell, B.Y., Levin, S.A., Robinson, T.P. et al., Global trends in antimicrobial use in food animals”, Proc Nat Acad Sci, 2015, 112 (18): 5649-5654.

  12. Shlaes, D.M., Sahm, D., Opiela, C. y Spellberg, B., “The fda reboot of antibiotics development”, Antimicrob Agents Chemother, 2013, 57 (10): 4605-4607.

  13. Munita, J.M. y Arias, C.A., “Mechanisms of antibiotics resistance”, Microbiol Spectr, 2016, 4 (2).

  14. Ahmed Khan, H., Kanwal Baig, F. y Mehboob, R., “Nosocomial infections: epidemiology, prevention, control and surveillance”, Asian Pac J Trop Biomed, 2017, 7 (5): 478-482.

  15. Cardoso, T. et al., “Classification of healthcare-associated infection: a systematic review 10 years after the first proposal”, bmc Medicine, 2014, 12 (40).

  16. Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E., Gilbert, D., Rice, L.B. et al., “Bad bugs, no drugs; no eskape! An update from the Infectious Diseases Society of America”, Clin Infect Dis, 2009, 48: 1-12.

  17. Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L. et al., “Discovery, research, and development of new antibiotics: the who priority list of antibiotic-resistant bacteria and tuberculosis”, Lancet Infect Dis, 2018, 18, 318-327.

  18. Elsner, H.A., Sobottka, I., Mack, D., Claussen, M., Laufs, R. y Wirth, R., “Virulence factors of Enterococcus faecalis and Enterococcus faecium blood culture isolates”, European J Clin Microb Infect Dis, 2000, 19 (1): 39-42.

  19. Yohaness Garoy, E., Berhane Gebreab, Y., Okoth Achila, O., Goitom Tekeste, D., Kesete, R., Ghirmany, R. et al., “Methicillin-resistant Staphylococcus aureus (mrsa): prevalence and antimicrobial sensitivity pattern among patinets. A multicenter study in Asmara, Eritrea”, Can J Infect Dis Medical Microbiol, 2019, disponible en: https://doi. org/10.1155/2019/8321834.

  20. Mónaco, M., Pimentel de Araujo, F., Cruciani, M., Coccia, E.M. y Pantosti, A., “Worldwide epidemiology and antibiotic resistance of Sataphylococcus aureus, Curr Top Microbiol Immunol, 2017, 409: 21-56.

  21. Calfee, D.P., “Recent advances in the understanding and management of Klebsiella pneumoniae [version 1; referees: 2 approved] F1000 Research 2017, 6(F1000 Faculty Rev): 1760 (doi: 10.12688/f1000research.11532.1).

  22. Magiorakos, A.P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G. et al., “Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance”, Clin Microbiol Infect, 2012, 18: 268-281.

  23. Poire, L., Madec, J.Y., Lupo, A., Schinik, A.K., Kieffer, N., Nordmann, P. et al., “Antimicrobial resistance in Escherichia coli”, Microbiol Spectr, 2018, 6 (4).

  24. Mesaros, N., Nordmann, P., Plésiat, P., Roussel-Delvallez, M., Van Eldere, J., Glupczynskil, Y. et al., “Pseudomonas aeruginosa: resistance and therapeutic optinos at the turn of the new millennium”, Clin Microbiol Inf, 2007, 13: 560-578.

  25. Livermore, D.M., “Of Pseudomonas porins, pumps and carbapenems”, J Antimicrob Chemother, 2001, 47: 247-250.




2020     |     www.medigraphic.com